公开(公告)号：US20110268733A1

公开(公告)日：2011-11-03

申请号：US13143253

申请日：2010-04-07

申请人： Yoshiharu Hiruma ,  Eisuke Tsuda ,  Takeshi Takizawa ,  Makiko NaKayama

发明人： Yoshiharu Hiruma ,  Eisuke Tsuda ,  Takeshi Takizawa ,  Makiko NaKayama

IPC分类号： A61K39/395 ,  C07H21/04 ,  A61P19/02 ,  C12N5/10 ,  A61P35/00 ,  C12P21/02 ,  C12N1/21 ,  C12N1/19 ,  C07K16/00 ,  A61P19/10

CPC分类号： C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/30

摘要： Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

摘要翻译： 本发明提供一种用于治疗和/或预防由破骨细胞强烈表达的基因编码的蛋白质的异常骨代谢的药物组合物。 具体提供含有特异性识别人Siglec-15并具有抑制破骨细胞形成活性的抗体的药物组合物等。

公开(公告)号：US08575316B2

公开(公告)日：2013-11-05

申请号：US13143253

申请日：2010-04-07

申请人： Yoshiharu Hiruma ,  Eisuke Tsuda ,  Takeshi Takizawa ,  Makiko Nakayama

发明人： Yoshiharu Hiruma ,  Eisuke Tsuda ,  Takeshi Takizawa ,  Makiko Nakayama

IPC分类号： C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C12N15/00 ,  C12N15/13 ,  C12N15/63

CPC分类号： C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/30

摘要： Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

摘要翻译： 本发明提供一种用于治疗和/或预防由破骨细胞强烈表达的基因编码的蛋白质的异常骨代谢的药物组合物。 具体提供含有特异性识别人Siglec-15并具有抑制破骨细胞形成活性的抗体的药物组合物等。

公开(公告)号：US09114131B2

公开(公告)日：2015-08-25

申请号：US13877779

申请日：2011-10-04

申请人： Ichiro Watanabe ,  Yoshiharu Hiruma ,  Eisuke Tsuda ,  Tatsuji Matsuoka ,  Toshiaki Ohtsuka ,  Tohru Takahashi ,  Toshinori Agatsuma ,  Sandra Miller ,  Robert Mühlbacher ,  Kathrin-Ladetzki Baehs ,  Steffen Runz ,  Ulrike Schubert ,  Ingrid Schuster ,  Dirk Ponsel

发明人： Ichiro Watanabe ,  Yoshiharu Hiruma ,  Eisuke Tsuda ,  Tatsuji Matsuoka ,  Toshiaki Ohtsuka ,  Tohru Takahashi ,  Toshinori Agatsuma ,  Sandra Miller ,  Robert Mühlbacher ,  Kathrin-Ladetzki Baehs ,  Steffen Runz ,  Ulrike Schubert ,  Ingrid Schuster ,  Dirk Ponsel

IPC分类号： A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/22 ,  C12N5/10 ,  C12N15/11 ,  C12N15/63 ,  C07K16/28 ,  A61K45/06

CPC分类号： A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/92

摘要： An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

摘要翻译： 能够结合抑制破骨细胞形成和/或破骨细胞骨吸收的Siglec-15的分离抗体或其功能片段。 抗体的重链包含CDRH1，其包含与SEQ ID NO：106具有至少80％序列同一性的序列，CDRH2包含与SEQ ID NO：107具有至少80％序列同一性的序列，以及CDRH3，其包含 具有与SEQ ID NO：35,45,55,65或80之一具有至少80％序列同一性的序列。抗体的轻链包含CDRL1，其包含与SEQ ID NO：73具有至少80％序列同一性的序列 或83，CDRL2，其包含与SEQ ID NO：108具有至少80％序列同一性的序列，和CDRL3，其包含与SEQ ID NO：40,50,60,70， 90，100或109。

公开(公告)号：US20130280276A1

公开(公告)日：2013-10-24

申请号：US13877779

申请日：2011-10-04

申请人： Ichiro Watanabe ,  Yoshiharu Hiruma ,  Eisuke Tsuda ,  Tatsuji Matsuoka ,  Toshiaki Ohtsuka ,  Tohru Takahashi ,  Toshinori Agatsuma ,  Sandra Miller ,  Robert Mühlbacher ,  Kathrin-Ladetzki Baehs ,  Steffen Runz ,  Ulrike Schubert ,  Ingrid Schuster ,  Dirk Ponsel

发明人： Ichiro Watanabe ,  Yoshiharu Hiruma ,  Eisuke Tsuda ,  Tatsuji Matsuoka ,  Toshiaki Ohtsuka ,  Tohru Takahashi ,  Toshinori Agatsuma ,  Sandra Miller ,  Robert Mühlbacher ,  Kathrin-Ladetzki Baehs ,  Steffen Runz ,  Ulrike Schubert ,  Ingrid Schuster ,  Dirk Ponsel

IPC分类号： A61K39/395 ,  A61K45/06

CPC分类号： A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/92

摘要： An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

摘要翻译： 能够结合抑制破骨细胞形成和/或破骨细胞骨吸收的Siglec-15的分离抗体或其功能片段。 抗体的重链包含CDRH1，其包含与SEQ ID NO：106具有至少80％序列同一性的序列，CDRH2包含与SEQ ID NO：107具有至少80％序列同一性的序列，以及CDRH3，其包含 具有与SEQ ID NO：35,45,55,65或80之一具有至少80％序列同一性的序列。抗体的轻链包含CDRL1，其包含与SEQ ID NO：73具有至少80％序列同一性的序列 或83，CDRL2，其包含与SEQ ID NO：108具有至少80％序列同一性的序列，和CDRL3，其包含与SEQ ID NO：40,50,60,70， 90，100或109。

公开(公告)号：US08546540B2

公开(公告)日：2013-10-01

申请号：US12677621

申请日：2008-10-08

申请人： Yoshiharu Hiruma ,  Eisuke Tsuda

发明人： Yoshiharu Hiruma ,  Eisuke Tsuda

IPC分类号： C07K16/00 ,  C07K16/46 ,  C07K16/28 ,  C12N5/20

CPC分类号： C07K16/2851 ,  A61K31/593 ,  A61K31/663 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

摘要： To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

公开(公告)号：US20120251485A1

公开(公告)日：2012-10-04

申请号：US13457967

申请日：2012-04-27

申请人： Yoshiharu Hiruma ,  Eisuke Tsuda

发明人： Yoshiharu Hiruma ,  Eisuke Tsuda

IPC分类号： A61K39/395 ,  A61K38/19 ,  A61P19/08 ,  A61P19/00 ,  A61P19/10

CPC分类号： C07K16/2851 ,  A61K31/593 ,  A61K31/663 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

摘要： To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

公开(公告)号：US10723800B2

公开(公告)日：2020-07-28

申请号：US13481016

申请日：2012-05-25

申请人： Yoshiharu Hiruma ,  Eisuke Tsuda

发明人： Yoshiharu Hiruma ,  Eisuke Tsuda

IPC分类号： A61K39/395 ,  A61K31/593 ,  A61K31/663 ,  A61K45/06 ,  A61K39/00 ,  C07K16/28

摘要： To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

公开(公告)号：US09090692B2

公开(公告)日：2015-07-28

申请号：US13457967

申请日：2012-04-27

申请人： Yoshiharu Hiruma ,  Eisuke Tsuda

发明人： Yoshiharu Hiruma ,  Eisuke Tsuda

IPC分类号： A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  A61K31/593 ,  A61K31/663 ,  A61K45/06

CPC分类号： C07K16/2851 ,  A61K31/593 ,  A61K31/663 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

摘要： To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

摘要翻译： 提供通过使用在破骨细胞中强烈表达的基因来检测异常骨代谢的方法; 筛选对异常骨代谢具有治疗和/或预防作用的化合物的方法; 以及用于治疗和/或预防异常骨代谢的药物组合物。 提供通过使用人Siglec-15基因的表达作为指标检测异常骨代谢的方法; 含有特异性识别人Siglec-15并具有抑制破骨细胞形成活性的抗体的药物组合物; 等等。

公开(公告)号：US20120230988A1

公开(公告)日：2012-09-13

申请号：US13481016

申请日：2012-05-25

申请人： Yoshiharu Hiruma ,  Eisuke Tsuda

发明人： Yoshiharu Hiruma ,  Eisuke Tsuda

IPC分类号： A61K39/395 ,  A61P19/10 ,  A61P35/00 ,  A61P19/08

摘要： To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

摘要翻译： 提供通过使用在破骨细胞中强烈表达的基因来检测异常骨代谢的方法; 筛选对异常骨代谢具有治疗和/或预防作用的化合物的方法; 以及用于治疗和/或预防异常骨代谢的药物组合物。 提供通过使用人Siglec-15基因的表达作为指标检测异常骨代谢的方法; 含有特异性识别人Siglec-15并具有抑制破骨细胞形成活性的抗体的药物组合物; 等等。

公开(公告)号：US20100209428A1

公开(公告)日：2010-08-19

申请号：US12677621

申请日：2008-10-08

申请人： Yoshiharu Hiruma ,  Eisuke Tsuda

发明人： Yoshiharu Hiruma ,  Eisuke Tsuda

IPC分类号： A61K39/395 ,  C12N5/16 ,  A61P19/00 ,  C07K16/18 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10

CPC分类号： C07K16/2851 ,  A61K31/593 ,  A61K31/663 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

摘要： To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

摘要翻译： 提供通过使用在破骨细胞中强烈表达的基因来检测异常骨代谢的方法; 筛选对异常骨代谢具有治疗和/或预防作用的化合物的方法; 以及用于治疗和/或预防异常骨代谢的药物组合物。 提供通过使用人Siglec-15基因的表达作为指标检测异常骨代谢的方法; 含有特异性识别人Siglec-15并具有抑制破骨细胞形成活性的抗体的药物组合物; 等等。